Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 19/20 | 0.72 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333731 | 1.00 | XPO1 (0.72) | XPO1HDAC1HDAC6 | |
| SCHEMBL1333735 | 1.00 | XPO1 (0.72) | XPO1HDAC1HDAC6 | |
| SCHEMBL1336049 | 0.89 | XPO1 (0.84) | XPO1 | |
| SCHEMBL1336052 | 0.89 | XPO1 (0.84) | XPO1 | |
| SCHEMBL1336054 | 0.89 | XPO1 (0.84) | XPO1 | |
| SCHEMBL1336003 | 0.85 | XPO1 (0.78) | XPO1 | |
| SCHEMBL1336175 | 0.85 | XPO1 (0.78) | XPO1 | |
| SCHEMBL1336173 | 0.85 | XPO1 (0.78) | XPO1 | |
| SCHEMBL1336000 | 0.85 | XPO1 (0.78) | XPO1 | |
| SCHEMBL1336170 | 0.85 | XPO1 (0.78) | XPO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | Karyopharm Therapeutics Inc. (US) | 2019-02-12 | — | — | US | claimed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | claimed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | claimed |
| US-20210308106-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS | UNIVERSITÉ PARIS CITÉ (FR) | 2021-10-07 | — | — | US | disclosed |
| US-11065230-B2 | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2021-07-20 | — | — | US | disclosed |
| US-20190247416-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS | Universite De Paris (FR) | 2019-08-15 | — | — | US | disclosed |
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | Karyopharm Therapeutics Inc. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | Karyopharm Therapeutics Inc. (US) | 2019-02-12 | — | — | US | disclosed |
| WO-2018050801-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2018-03-22 | — | — | WO | disclosed |
| US-9675590-B2 | Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2017-06-13 | — | — | US | disclosed |
| US-20170100378-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DA LA RECHERCHE MÉDICALE) (FR) | 2017-04-13 | — | — | US | disclosed |
| US-20160304500-A1 | Methods of Promoting Wound Healing Using CRM1 Inhibitors | Karyopharm Therapeutics Inc. | 2016-10-20 | — | — | US | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2014-06-05 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513230-B2 | Nuclear transport modulators and uses thereof | KARYOPHARM THERAPEUTICS, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| WO-2011109799-A1 | NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247416-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS | XPOT, XPO1, XPO4 | XPO1 2/4885HDAC1 3109/4885HDAC6 2301/4885 |
| US-11065230-B2 | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis | XPOT, XPO1, XPO4 | XPO1 2/4885HDAC1 3109/4885HDAC6 2301/4885 |
| US-10202366-B2 | Methods of promoting wound healing using CRM1 inhibitors | XPO1, XPA, ERCC2 | XPO1 1/4885HDAC1 89/4885HDAC6 566/4885 |
| US-20140155370-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885HDAC1 434/4885HDAC6 1967/4885 |
| US-20110275607-A1 | NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | XPO1, NXF1, XPOT | XPO1 1/4885HDAC1 434/4885HDAC6 1967/4885 |
| US-20210308106-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC MASTOCYTOSIS | XPOT, XPO1, XPO4 | XPO1 2/4885HDAC1 3109/4885HDAC6 2301/4885 |
| US-20170100378-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES | GATAD2A, KEAP1, XPO1 | XPO1 3/4885HDAC1 1438/4885HDAC6 418/4885 |
| US-20160304500-A1 | Methods of Promoting Wound Healing Using CRM1 Inhibitors | XPO1, KEAP1, COL1A1 | XPO1 1/4885HDAC1 82/4885HDAC6 569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.